# Shingles Vaccine Shows New Link to Lower Cardiovascular Risk
A new analysis reveals that people who receive the shingles vaccine may reduce their cardiovascular disease risk by approximately 9 percent. This finding expands the known benefits of the Shingrix vaccine beyond its primary purpose of preventing herpes zoster infections in adults over 50.
Researchers examining existing data discovered an association between shingles vaccination and decreased rates of heart attack, stroke, and other major cardiovascular events. The connection appears strongest in older adults and those with existing cardiovascular risk factors. This discovery adds to growing evidence that certain vaccines offer protective effects beyond their targeted illnesses.
The mechanism behind this protective effect remains under investigation. One leading theory involves the inflammatory response. Shingles infection triggers significant inflammation throughout the body, which research has linked to cardiovascular events. By preventing shingles through vaccination, people may avoid the inflammatory cascade that increases heart disease risk. Chronic infection and inflammation represent known cardiovascular risk factors, so blocking viral reactivation could have downstream cardiac benefits.
Shingrix, the recombinant zoster vaccine approved by the FDA, became the recommended shingles vaccine for adults 50 and older in 2017. The shot replaced Zostavax, an older live-attenuated vaccine, due to superior efficacy rates exceeding 90 percent. Unlike older vaccines, Shingrix requires two doses given two to six months apart.
The cardiovascular connection emerged from comprehensive reviews of clinical trial data and observational studies. Researchers tracked patients who received Shingrix and compared their cardiovascular outcomes to unvaccinated controls. The 9 percent risk reduction represents a modest but meaningful protection at the population level. For context, this protection magnitude approaches what some cardiovascular medications achieve.
Previous research has established that shingles itself carries immediate cardiovascular risks. Patients experiencing acute shingles infection show elevated rates of stroke and heart attack during the infection period. The pain and systemic inflammation from herpes zoster activation stress the cardiovascular system. Vaccination prevents this acute threat while potentially offering long-term protection through reduced overall inflammatory burden.
The findings matter for vaccination counseling discussions. Adults aged 50 and older already have strong reasons to get Shingrix, given shingles' painful complications including postherpetic neuralgia that can persist for months or years. The cardiovascular angle provides another evidence-based justification, particularly for those with heart disease, diabetes, or other cardiovascular conditions.
Healthcare providers emphasize that Shingrix remains recommended primarily for preventing shingles and its complications. The cardiovascular benefit serves as a secondary advantage rather than the primary indication. However, this additional protective effect strengthens the case for vaccination compliance in older populations where cardiovascular disease represents a leading health threat.
For people considering vaccination, the safety profile favors proceeding. Common side effects like arm soreness, mild fever, or temporary fatigue resolve within days. Serious adverse events remain rare and consistent with other recombinant vaccines. The CDC and immunization experts maintain that the benefits of Shingrix vaccination substantially outweigh potential risks for adults over 50.